Importance: Diagnostic tests are often ordered by physicians in patients with a low pretest probability of disease to rule out conditions and reassure the patient.
M
ANY PATIENTS PRESENT in primary care with symptoms that are not caused by serious illness. Approximately one-sixth of primary care visits and more than one-third of referrals from primary to secondary care occur for symptoms for which no organic pathology is apparent. [1] [2] [3] [4] Such symptoms with a low probability of disease pose a problem for clinicians and health services in terms of whether or how far to perform diagnostic tests. 5 Although clinical guidelines promote the rational use of diagnostic tests, 6 clinicians often order these tests for patients who do not meet these criteria. Physicians commonly express the belief that patients want these diagnostic tests and that the tests reassure patients 3, 7 ; consequently, they may propose such tests more often than patients actually seek them. 8, 9 We performed a systematic review to measure the effect of diagnostic tests on reassurance in patients with a low probability of serious disease. Because a previous systematic review identified very few trials that directly measured reassurance, 13 we expanded the concept of reassurance to include the following 4 separate components and consequences: the specific concern that symptoms might represent serious illness (illness concern), nonspecific anxiety, persistence of the symptoms, and subsequent primary care visits.
METHODS
We performed a systematic review and meta-analysis of published trials following meta-analysis guidelines 14 and using the preferred reporting items for systematic review and meta-analysis guidelines (the PRISMA statement). 15 The protocol for the review is held by the authors. Because this study did not involve individual patients, ethical approval was not required.
SEARCH STRATEGY
We performed a systematic search of the OVID MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE, PsychINFO, CINAHL, and ProQuest Dissertations electronic databases for publications from inception through December 31, 2011. The search was designed to be sensitive rather than specific and identified randomized controlled trials that included the following search terms: reassur*, anxi*, quality of life, or satisfaction (1 of these); investigat*, test*, imag*, x-ray, radiography, endoscopy, colonoscopy, or scan (1 of these); and negativ*, normal, or benign (Ն1 of these) (eAppendix; http: //www.jamainternalmed.com). We included original articles and checked the reference lists of relevant systematic reviews for trials that met the eligibility criteria. Trials published in languages other than English were eligible for inclusion. We also obtained references cited in other identified publications and considered them for inclusion.
REVIEW OF ELIGIBILITY CRITERIA
We considered trials for inclusion if they met the following 5 criteria:
1. The study design was a randomized controlled trial (including cluster trials).
2. Participants included adults (aged Ն18 years) with symptoms indicating a low probability of serious disease.
3. Interventions consisted of initial diagnostic testing in primary or secondary care for symptoms with a low probability of serious disease based on clinical features. Tests included imaging (radiography, computed tomography, magnetic resonance imaging, and ultrasonography), endoscopy, and cardiac testing. For trials with more than 2 intervention arms, we included the intervention most closely representing testing alone.
4. Comparisons included initial nontesting. Control groups received usual care or empirical treatment. Trials that permitted subsequent diagnostic testing if symptoms persisted were eligible.
5. Outcomes included illness concern, generalized or nonspecific anxiety, change in the original symptoms, and subsequent use of health care resources in primary care defined as subsequent visits to a physician. We defined outcomes as short term (Յ3 months) or long term (Ͼ3 months); if multiple points after 3 months were available, we used those closest to 1 year.
Trials were excluded if they were not published in a peer-reviewed journal or were undertaken in tertiary care (eg, a spinal surgery center) 16 where the prevalence of serious conditions was expected to be high. In addition, we excluded trials for which outcomes were not reported at baseline and completion.
TRIAL SELECTION AND ANALYSIS
The methods for trial selection and assessment of risk of bias (using the Cochrane risk of bias tool 17 ) are described in detail in the eMethods. Eligible data were converted to odds ratios and displayed as forest plots. If statistical heterogeneity was low to moderate (I 2 Ͻ50%), we performed random-effects meta-analysis using methods from the Cochrane Handbook 18 ; details of this procedure are available in the eMethods. We converted odds ratios for the use of health care resources to a number needed to investigate. Figure 1 shows the yield of relevant literature identified from the search strategy and the application of the review eligibility criteria. 
RESULTS

STUDY CHARACTERISTICS
We found 14 trials comparing testing with nontesting; these trials included 3828 patients. All the trials were published in English. Nine trials took place in a general practice/ family medicine setting, [19] [20] [21] [22] [23] [24] [25] [26] [27] and 5, in a general or specialist internal medicine practice setting. [28] [29] [30] [31] [32] Eight of the trials involved diagnostic testing for dyspepsia (endoscopy or radiography) [19] [20] [21] [22] [23] 27, 28, 30 ; 3 involved radiography for back pain. 25, 26, 29 One each involved blood tests and electrocardiography for chest pain, 32 imaging for headache, 31 and continuous event recorders for palpitations. 24 With the exception of 2 trials, 19, 27 studies involved recent rather than persistent symptoms. Several studies specified a minimum duration to exclude trivial conditions for which diagnostic testing may not be clinically necessary. Trials comparing testing with nontesting reported outcome data on illness concern, 25, 31, 32 nonspecific or general anxiety, 24, 26 symptoms, 19, [21] [22] [23] [25] [26] [27] [28] [29] [30] 32 and subsequent primary care visits. [19] [20] [21] [22] [23] [25] [26] [27] [28] 31, 32 Ten trials reported short-term data 20,23-27,29-32 and 13, long-term data. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [30] [31] [32] Long-term follow-up varied from 4 to 18 months. Substantial variation existed between trials in the measurement tools used. Trial characteristics are summarized in Table 1 and main outcomes in Table 2 . Figure 2 summarizes the risk of bias for all included trials. All trials were randomized at the level of the individual patient. No study had clearly inadequate randomization procedures or allocation concealment, although details were unclear in 6 trials for each of these criteria. 19, 24, 27, 29, 30, 32 One study used a modified Zelen preconsent randomization to minimize the risk of patients feeling more anxious about being declined a diagnostic test. 31 Most studies were of moderate quality; outcomes from those with the highest quality 23, 27, 31, 35 did not differ noticeably from the other outcomes. No trials blinded the patients or their clinicians to the intervention, and only 1 trial reported adequate blinding of the outcome assessor at follow-up. 31 Most (but not all) patients randomized to diagnostic tests received them. Most trials included the option for patients allocated to no testing to receive subsequent diagnostic testing. The rates of later testing in patients randomized to nontesting varied, from 10% to 66% for endoscopy to 1.5% to 13% for other diagnostic tests. Three trials did not provide clear information about subsequent testing. 20, 24, 29 Attrition rates varied between trials and with the duration of follow-up. Short-term outcome data were available for 75% to 100% of randomized patients; longer-term data were available for 71% to 100%. Few trials used statistical techniques to adjust for the effects of loss to follow-up. 22, 24, 31 
RISK OF BIAS
ILLNESS CONCERN
Three trials examined illness concern in relation to magnetic resonance imaging for patients with headache, 31 lumbar spine radiography for patients with back pain, 25 and blood tests and electrocardiography in patients with chest pain. 32 Heterogeneity between studies was low (I 2 = 0%). Investigation was associated with no significant reduction in illness concern in the short (odds ratio, 0.90 [95% CI, 0.51- 
ANXIETY
Only 2 trials examined nonspecific or generalized anxiety: one in relation to lumbar radiography for patients with back pain 26 and the other in relation to the use of a continuous cardiac event recorder for patients with palpitations. 24 Heterogeneity between studies was low (I 2 = 0%). We observed a statistically insignificant increase in anxiety at longer-term follow-up in patients who underwent investigation, as shown in 
SYMPTOMS
Eleven trials reported the original symptoms after 1 or more follow-up periods. 19, [21] [22] [23] [25] [26] [27] [28] [29] [30] 32 Heterogeneity between studies was high in the short term (I 2 = 67%) and low in the longer term (I 2 = 0%). Metaanalysis ( Figure 5 ) indicated no effect of diagnostic testing on symptoms in the longer term (odds ratio, 0.99 [95% CI, 0.85-1.15]). 
SUBSEQUENT PRIMARY CARE VISITS
Eleven trials examined primary care visit rates after the intervention. [19] [20] [21] [22] [23] [25] [26] [27] [28] 31, 32 Eight trials used case note reviews [20] [21] [22] [23] [26] [27] [28] 31 and 3 used patient self-report. 19, 25, 32 Individual and overall effects are shown in Figure 6 , which indic a t e s m a r k e d h e t e r o g e n e i t y between trials (I 2 = 80%). Most of this heterogeneity arose from 2 trials: one with a very small number of participants 20 and the other an older trial that predated Helicobacter pylori eradication for peptic ulcer disease. 19 When these 2 trials were excluded, heterogeneity was reduced (I 2 = 33%), and the overall effect was a reduction in subsequent visit rates of 0.77 (0.62-0.96). The rates of repeated visits for control patients were 60% in dyspepsia trials, with a number n e e d e d t o i n v e s t i g a t e o f 1 6 (95% CI, 8-100), and 20% in back pain trials, with a number needed to investigate of 26 (95% CI, 15-155).
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MAIN FINDINGS
This systematic review indicates that patients' illness concern, health anxiety, and symptoms are not reduced by diagnostic testing in the short or the long term. Subsequent use of health care resources may be reduced by diagnostic testing, although the number of patients needed to investigate and avoid 1 subsequent visit varied from 16 to 26 depending on the symptom. In the context of widespread belief that diagnostic testing reassures patients, these findings suggest that physicians overestimate the value of testing when the probability of serious disease is low.
STRENGTHS AND LIMITATIONS
Although previous systematic reviews have used a narrow definition of reassurance 13 or have been limited to 1 specific clinical problem, 37, 38 we included a broader assessment of reassurance by including the reduction of illness concern and the expected consequences of reassurance; we also included a wide range of clinical problems. This approach risks comparing trials that are too dissimilar and for which metaanalysis may be inappropriate; however, we took the view that models of symptom appraisal and reassurance are consistent across contexts [10] [11] [12] and that all trials centered on the decision to perform diagnostic testing or not. Substantial heterogeneity was seen only for the use of health care resources and, because the number of trials was small, we did not perform a formal subgroup comparison. Outcome measures varied from the well validated (such as the 36-Item Short Form Health Survey) to the ad hoc; the poorly validated measures might have been insufficiently sensitive to change.
The studies in this review were conducted in different places and times during which the practice of medicine and the expectations of patients changed. The study that showed the greatest influence of diagnostic testing on reassurance 19 was for peptic ulcer disease in the 1980s, when surgical treatment was common and before the recognition of H pylori. Most of the eligible studies were conducted in European health care systems, where access to diagnostic testing may be more constrained than in US health care. We examined reassurance for patients only; we did not examine the reassurance (including the reassurance that they were less likely to be sued) that diagnostic tests provided for physicians. A health economic analysis was beyond the scope of this review; however, because the cost of a primary care consultation is less than the cost of most diagnostic tests and because several tests were required to avert 1 consultation, the balance would not favor testing.
We did not examine differential effects of anxiety at baseline on subsequent reassurance. One study reported a prespecified comparison between more and less anxious patients and found that illness concern was reduced more by diagnostic testing in patients with high anxiety levels, but these data were not available from other trials. 31 Although our analysis highlights the limited value of diagnostic testing in terms of reassurance, it does not address the wider role of investigations in identifying disease or allowing the physician to rule out a particular differential diagnosis. Although the prevalence of serious disease such as cancer in the eligible trials varied from less than 0.5% to 3%, our findings do not address what pretest probability of disease constitutes an appropriate threshold for investigation to obtain a diagnosis. In addition, our find- Figure 3 . Effect of diagnostic testing on reduction of illness concern. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using random-effects models. OR indicates odds ratio. ings do not contradict guidelines for rational requesting of tests that balance benefits against harms. We did not find studies of complex or chronic symptoms. However, persistent symptoms with negative test results are associated with frustration and dissatisfaction.
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INTERPRETATION
We found the use of diagnostic testing did little to reassure patients, and this finding is inconsistent with beliefs expressed by physicians. 3, 7 One explanation is that the reassurance obtained by patients from negative diagnostic test results is transient. Observational studies suggest that illness concerns reappear within hours of receiving a normal (negative) test result, 40, 41 whereas the trials in our review measured effects after weeks or months. The mechanism of transient reassurance appears to be predominantly emotional-a fleeting sense of relief-in contrast to a more sustained cognitive reassurance. 10 One trial included in the review attempted to place a value on reassurance and found that patients were willing to pay for the reassurance of normal findings on spine radiography, although no discernible effect was observed on measures of concern. 25 Thus, patients and physicians may value the immediate relief of reassurance, although the benefits are not sustained. We found a small reduction in subsequent primary care visits after diagnostic testing, but this reduction required several patients to undergo testing to prevent 1 visit.
RECOMMENDATIONS FOR RESEARCH AND PRACTICE
Because the number of trials in this review is relatively small, further trials may demonstrate an effect of diagnostic testing on reassurance among patients with symptoms indicating a low probability of disease. However, the small effect sizes are in keeping with the postulated psychological and behavioral mechanisms underlying symptom appraisal 11 and reassurance. 10, 12 Thus, concentration of future research on the following 2 questions may be more important: (1) how to maximize the reassurance value of diagnostic tests and (2) whether reassurance should be targeted to particular patients. Three trials have reported that brief interventions to increase the acceptability of negative test results lead to improved reassurance, [42] [43] [44] and theoretical work supports this finding. 45 Targeting interventions (including reassurance and cognitive-based rehabilitation) to patients at higher risk of persistent symptoms is effective in patients with low back pain, 46 and diagnostic testing accompanied by enhanced explanation can be an appropriate strategy. Meanwhile, physicians and health care organizations should be aware of the limitations of the transient reassurance provided by negative diagnostic test results and should limit tests to those that influence clinical management. In summary, commonly used diagnostic tests have little effect on several aspects of reassurance in patients whose symptoms indicate a low pretest probability of serious illness. Heterogeneity: τ 2 = 0.00; χ 2 = 7.46 (P = .59); I 2 = 0% Test for overall effect: z = 0.13 (P = .90) 5 9 Figure 5. Effect of diagnostic testing on presenting symptoms. The size of the data marker corresponds to the relative weight assigned in the pooled analysis using random-effects models. OR indicates odds ratio. Figure 6 . Effect of diagnostic testing on primary care visits. OR indicates odds ratio.
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